Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Shanghai Kaibao Pharmaceutical Co's Net Margin % or its related term are showing as below:
SZSE:300039'
s Net Margin % Range Over the Past 10 Years
Min: 11.69 Med: 17.52 Max: 25.49
Current: 25.03
SZSE:300039's Net Margin % is ranked better than 91.45% of 959
companies
in the Drug Manufacturers industry
Industry Median: 5.32
vs SZSE:300039: 25.03
Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Shanghai Kaibao Pharmaceutical Co Net Margin % Related Terms
Shanghai Kaibao Pharmaceutical Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Kaibao Pharmaceutical Co Net Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Kaibao Pharmaceutical Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Kaibao Pharmaceutical Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Kaibao Pharmaceutical Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Shanghai Kaibao Pharmaceutical Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Kaibao Pharmaceutical Co (SZSE:300039) has a Net Margin % of 22.90% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Shanghai Kaibao Pharmaceutical Co and its competitors. This is 31% above median its historical median of 17.52. Over the past decade, Shanghai Kaibao Pharmaceutical Co's Net Margin % has ranged from 11.69 to 25.49. According to the industry distribution chart, Shanghai Kaibao Pharmaceutical Co ranks #82 out of 959 companies in the Drug Manufacturers industry, placing it in the top 8.6%.
Is Shanghai Kaibao Pharmaceutical Co's Net Margin % too high?
Shanghai Kaibao Pharmaceutical Co's current Net Margin % of 22.90% is 31% above median its 10-year median of 17.52. Over the past 10 years, this metric has ranged from a low of 11.69 to a high of 25.49. The Drug Manufacturers industry median Net Margin % is 5.32. Shanghai Kaibao Pharmaceutical Co's value of 22.90% is 330.5% above this industry median. Based on the distribution chart, Shanghai Kaibao Pharmaceutical Co ranks #82 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Kaibao Pharmaceutical Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Kaibao Pharmaceutical Co's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Kaibao Pharmaceutical Co ranks #82 out of 959 companies for Net Margin %. This places Shanghai Kaibao Pharmaceutical Co in the top 9% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.32. Shanghai Kaibao Pharmaceutical Co's value of 22.90% is 330.5% above this benchmark. Historically, Shanghai Kaibao Pharmaceutical Co's own Net Margin % has ranged from 11.69 to 25.49 over the past decade. While the company's 10-year median is 17.52 vs. the industry median of 5.32, Shanghai Kaibao Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.32, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Kaibao Pharmaceutical Co's current Net Margin % of 22.90% is 330.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Shanghai Kaibao Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Kaibao Pharmaceutical Co's current Net Margin % is 22.90%, which is 31% above median its own 10-year median of 17.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Kaibao Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Kaibao Pharmaceutical Co (SZSE:300039) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥4.65, compared to a current price of ¥6.03 — trading 29.7% above its estimated fair value. The current Net Margin % is 22.90%, which is 31% above median its 10-year median of 17.52 and 330.5% above the Drug Manufacturers industry median of 5.32. Shanghai Kaibao Pharmaceutical Co's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Shanghai Kaibao Pharmaceutical Co (SZSE:300039), the current Net Margin % is 22.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Kaibao Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥6.03 is trading 29.7% above its estimated GF Value™ of ¥4.65.
GuruFocus considers Shanghai Kaibao Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SZSE:300039:
Net Margin %: 22.90% (31% above median its 10-year median of 17.52)
GF Value™: ¥4.65 vs. price of ¥6.03 (29.7% above fair value)
Industry Position: 330.5% above the Drug Manufacturers median (#82 of 959)
No single metric tells the full story. See the SZSE:300039 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Kaibao Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in research, development, production, and sales of modern Chinese medicine. The company produces traditional Chinese medicines in the form of solid dosage, oral liquids, and small volume injections. Its main product is Tanreqing injection is mainly used for pneumonia, acute and chronic bronchitis and upper respiratory tract infection.
72GF Score
Get the complete analysis for SZSE:300039
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300039 has been successfully added to your 
